Jaguar Health Inc JAGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Jaguar Health Provides Update Regarding Special Stock Dividend
-
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
-
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
-
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
-
Jaguar Health Announces a Special Stock Dividend
-
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
-
Jaguar Health Receives Fee Waivers from FDA
-
Jaguar Health, Inc. Announces Reverse Stock Split
Trading Information
- Previous Close Price
- $4.59
- Day Range
- $3.25–4.20
- 52-Week Range
- $2.35–1,160.25
- Bid/Ask
- $3.39 / $3.56
- Shares Outstanding
- 1.95M
- Market Cap
- $6.86M
- Volume/Avg
- 887,989 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 47
- Website
- http://www.jaguar.health
Valuation
|
Metric
|
JAGX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.20 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
JAGX
Financial Strength
|
Metric
|
JAGX
|
|---|---|
Quick Ratio | 0.16 |
Current Ratio | 0.69 |
Interest Coverage | −35.99 |
Quick Ratio
JAGX
Profitability
|
Metric
|
JAGX
|
|---|---|
Return on Assets (Normalized) | −46.26% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −60.78% |
Return on Assets
JAGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&&!bMD@ | LOCK|r@Mp& | $127B | |||
| Moderna Inc
MRNA
| LOCK|s@wF!Ym | LOCK|Lc | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?W>K#K% | LOCK|TtYY | $81B | |||
| argenx SE ADR
ARGX
| LOCK|?ssP<s& | LOCK|Mp | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|FSMWTC@ | LOCK|FX | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#FwKJL | LOCK|%W^lP | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|F?LqNb&v | LOCK|xh$@$ | $27B | |||
| Incyte Corp
INCY
| LOCK|fFc&W< | LOCK|wf | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|yS?kCl& | LOCK|TP | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|tt?L&? | LOCK|k& | $14B |
United States